Naomi Fujioka

Emailfujio002umnedu

Research activity per year

If you made any changes in Pure these will be visible here soon.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Fingerprint

The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

1 Similar Profiles

6 Active
8 Finished

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of SQZ-PBMC-HPV asMonotherapy and in Combination with Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+Patients with HPV16+ Recurrent, Locally Advanced or Metast
Fujioka, N.
SQZ BIOTECHNOLOGIES COMPANY
3/14/21 → 3/30/26
Project: Research project
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects withPreviously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Fujioka, N.
Astellas Pharma US, Inc.
10/13/20 → 10/31/25
Project: Research project
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell LungCancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127
Fujioka, N.
BIG TEN CANCER RESEARCH CONSORTIUM
8/30/18 → 8/30/23
Project: Research project
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of CombinationTreatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent / MetastaticHuman Papilloma Virus Associated Head and Neck Squamous
Fujioka, N.
AstraZeneca
5/16/18 → 5/30/23
Project: Research project
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alonefollowing Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer(NSCLC)
Fujioka, N.
BIG TEN CANCER RESEARCH CONSORTIUM
1/1/18 → 1/31/23
Project: Research project

22 Article
3 Review article
1 Letter

Exceptional response to afatinib in a patient with persistent G719A EGFR -mutant NSCLC
Kulkarni, A. A., Fujioka, N., Reinhardt, L., Patel, M. R. & Kratzke, R. A., Mar 1 2022, In: Lung Cancer Management. 11, 1, LMT54.
Research output: Contribution to journal › Article › peer-review

Open Access
Preparation of a Beverage Containing Freeze-Dried Watercress for a Clinical Trial of Carcinogen and Toxicant Detoxification
Bonorden, M. J. L., Carmella, S. G., Ballinger, O. T., Williams, J., Dorn, I., Vanderloo, H., Fujioka, N., Hatsukami, D. K. & Hecht, S. S., Mar 1 2022, In: Cancer Prevention Research. 15, 3, p. 143-150 8 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience
Peña Pino, I., Ma, J., Hori, Y. S., Fomchenko, E., Dusenbery, K., Reynolds, M., Wilke, C., Yuan, J., Srinivasan, E., Grabowski, M., Fecci, P., Domingo-musibay, E., Fujioka, N., Barnett, G. H., Chang, V., Mohammadi, A. M. & Chen, C. C., Jan 2022, In: Journal of neuro-oncology. 156, 2, p. 295-306 12 p.
Research output: Contribution to journal › Article › peer-review
Cytomegalovirus infection in malignant pleural mesothelioma
Hunter-Schlichting, D. V., Kelsey, K. T., Demmer, R., Patel, M., Bueno, R., Christensen, B., Fujioka, N., Kolarseri, D. & Nelson, H. H., Aug 2021, In: PloS one. 16, 8 August, e0254136.
Research output: Contribution to journal › Article › peer-review

Open Access
Mortality from COVID-19 in patients with lung cancer
Kulkarni, A. A., Wilson, G., Fujioka, N. & Patel, M. R., Jun 11 2021, In: Journal of Cancer Metastasis and Treatment. 7, 31.
Research output: Contribution to journal › Review article › peer-review

Open Access

Naomi Fujioka

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Network

Dive into details

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of SQZ-PBMC-HPV asMonotherapy and in Combination with Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+Patients with HPV16+ Recurrent, Locally Advanced or Metast

An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects withPreviously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell LungCancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127

A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of CombinationTreatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent / MetastaticHuman Papilloma Virus Associated Head and Neck Squamous

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alonefollowing Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer(NSCLC)

Exceptional response to afatinib in a patient with persistent G719A EGFR -mutant NSCLC

Preparation of a Beverage Containing Freeze-Dried Watercress for a Clinical Trial of Carcinogen and Toxicant Detoxification

Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience

Cytomegalovirus infection in malignant pleural mesothelioma

Mortality from COVID-19 in patients with lung cancer

Naomi Fujioka

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Network

Projects

Research output